Article
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Oncotarget - 22 Sept 2015
Formisano Luigi, D'Amato Valentina, Servetto Alberto, Brillante Simona, Raimondo Lucia, Di Mauro Concetta, Marciano Roberta, Orsini Roberta Clara, Cosconati Sandro, Randazzo Antonio, Parsons Sarah J, Montuori Nunzia, Veneziani Bianca Maria, De Placido Sabino, Rosa Roberta, Bianco Roberto
Abstract excerpt
Resistance to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, often related to Ras or secondary EGFR mutations, is a relevant clinical issue in Non-Small Cell Lung Cancer (NSCLC). Although Src TK has been involved in such resistance, clinical development of its inhibitors has been so far limited. To better define the molecular targets of the Src TKIs saracatinib, dasatinib and bosutinib, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.